Literature DB >> 9679554

Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer.

T Nishimura1, K Newkirk, R B Sessions, P A Andrews, B J Trock, A A Rusmussen, E A Montogomery, E K Bischoff, M H Hanigan, K J Cullen.   

Abstract

We examined the correlation between response to platinum-based chemotherapy and expression of glutathione S-transferase (GST), gamma-GGT (both by immunohistochemistry) and gamma-GCS (by in situ hybridization) in 51 patients with head and neck cancer, who received a total of 56 courses of chemotherapy. The overall response rate for the 56 chemotherapy treatment courses was 48%. The overall response rate (CR, PR) for patients with low GST scores was 88% (21 of 24), while among the patients with high GST scores, the overall response rate was 19% (6 of 32, P = 0.001). Patients with a low GST score were 4.7 times more likely to respond to chemotherapy than patients with high GST scores. GST scores corresponded to response in 84% of cases. Among 33 patients treated with chemotherapy for relapsed disease, the overall response rate for patients with low GST score was 70% (7 of 10), while among the patients with high GST scores, the overall response rate was 8.7% (2 of 23), P < 0.001). In contrast, both gamma-GCS and gamma-GGT showed a range of expression in these samples, but there was no significant correlation with treatment response. We conclude that GST expression correlates well with response to platinum based chemotherapy in head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679554     DOI: 10.1016/s0009-2797(97)00161-0

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  8 in total

1.  Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin.

Authors:  M H Hanigan; E D Lykissa; D M Townsend; C N Ou; R Barrios; M W Lieberman
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity.

Authors:  Danyelle M Townsend; Kenneth D Tew; Lin He; Jarrod B King; Marie H Hanigan
Journal:  Biomed Pharmacother       Date:  2008-09-07       Impact factor: 6.529

3.  Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin.

Authors:  Christina Peklak-Scott; Pamela K Smitherman; Alan J Townsend; Charles S Morrow
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

4.  Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation.

Authors:  L Mannarini; G Bertino; P Morbini; C Villa; M Benazzo
Journal:  Acta Otorhinolaryngol Ital       Date:  2007-08       Impact factor: 2.124

5.  Cisplatin nephrotoxicity: molecular mechanisms.

Authors:  Marie H Hanigan; Prasad Devarajan
Journal:  Cancer Ther       Date:  2003

6.  A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.

Authors:  Hark Kyun Kim; Il Ju Choi; Chan Gyoo Kim; Hee Sung Kim; Akira Oshima; Aleksandra Michalowski; Jeffrey E Green
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

7.  NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.

Authors:  Anna Bratasz; Karuppaiyah Selvendiran; Tomasz Wasowicz; Andrey Bobko; Valery V Khramtsov; Louis J Ignarro; Periannan Kuppusamy
Journal:  J Transl Med       Date:  2008-02-26       Impact factor: 5.531

8.  Nuclear localization of glutamate-cysteine ligase is associated with proliferation in head and neck squamous cell carcinoma.

Authors:  Didier Dequanter; Maureen VAN DE Velde; Isabelle Bar; Vincent Nuyens; Alexandre Rousseau; Nathalie Nagy; Luc Vanhamme; Michel Vanhaeverbeek; Dany Brohée; Paul Delrée; Karim Boudjeltia; Philippe Lothaire; Pierrick Uzureau
Journal:  Oncol Lett       Date:  2016-04-19       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.